Pfizer and BioNTech: Vaccine 95% Effective in Final Efficacy Analysis of Phase 3 Trial

Pfizer Inc said on Wednesday that the final efficacy analysis of phase 3 trial of the coronavirus vaccine it develops with BioNTech has shown to be 95% effective, as reported by Reuters.

“Efficacy of COVID-19 vaccine was consistent across age, race and ethnicity demographics.”

“Planning to file for US emergency use authorization of COVID-19 vaccine within days.”

“Concluded phase 3 study with 170 confirmed cases of covid; 162 of those cases were in the placebo arm.”